Laboratorios Farmaceuticos Rovi stock
Price history
+9.55% over the period1 year: from €57.60 (November 20, 2025) to €63.10 (November 20, 2026), +9.55%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €63.10 |
| October 30, 2026 | €62.55 |
| September 30, 2026 | €58.80 |
| August 31, 2026 | €60.60 |
| July 31, 2026 | €58.55 |
| June 30, 2026 | €57.85 |
| May 29, 2026 | €59.30 |
| April 30, 2026 | €79.40 |
| March 31, 2026 | €80.75 |
| February 27, 2026 | €84.75 |
| January 30, 2026 | €71.90 |
| December 31, 2025 | €63.50 |
| November 28, 2025 | €59.45 |
| November 20, 2025 | €57.60 |
At a glance
The company
Manufactures and markets pharmaceutical products and provides contract-manufacturing services for injectable and solid pharmaceutical forms
Latest results
Quarter to June 30, 2026 · EPS €1.47
TickerLandia's take on Laboratorios Farmaceuticos Rovi
- Priced as usual relative to earnings: P/E on the latest fiscal year 23 vs a median of 25 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 16 vs 19 (−17%) in a group of 10.
- Strong point: Profitability (72/100 in its group). Weak point: Dividend (39/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−27.22% from the 52-week high
Analysts · 9 analysts
Average target€75.22+19.21% vs. price
Buy 4 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: Laboratorios Farmaceuticos Rovi
Compared with similar companies: high profitability, high financial strength, and low dividend.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage51
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 17.5 63 P/E (trailing 12 months) 16.0 19 Forward P/E 19.9 49 Price/book 4.29 65 Price/sales 4.04 62 Profitabilityhigh72
How much it earns on revenue and capital.
Metric Value Position in group ROE 28.7% 94 ROA 10.2% 76 Operating margin 20.2% 53 Gross margin 66.2% 58 Net margin 24.8% 78 Earnings stabilityaverage58
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.2% 54 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage59
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +26.40% 74 Average revenue growth (3 years) −3.12% 7 Earnings growth (year over year) +246.69% 96 Financial strengthhigh69
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.12 58 Interest coverage 67.5 73 Debt/equitycounts in reverse: lower means more financial strength 0.13 74 Current ratio 2.68 71 Dividendlow39
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 19 years 53 Dividend yield 1.5% 44 Payout ratio 23.5% 21 Market momentumaverage57
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +0.67% 56 Distance from 200-day average −3.91% 42 1-year return +9.55% 52 Relative strength (3 months) +10.58% 78 Riskaverage49
How much the price swings.
Metric Value Position in group Beta (1 year) 0.39 19 Volatility (60 days) 27.3% 48 Maximum drawdown (12 months) 37.3% 81
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Laboratorios Farmaceuticos Rovi is priced as in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Laboratorios Farmaceuticos Rovi's P/E today is 23.0, in line with the median of its last 10 fiscal years (25.1; between 9.66 and 49.9 from 2016 to 2025). Laboratorios Farmaceuticos Rovi's P/E (trailing 12 months): 16.0, −17% against the median of a group of 10 similar companies (19.4).
Compared with 10 similar companies
| Metric | Laboratorios Farmaceuticos Rovi | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 16.0 | Low | |
| Forward P/E | 19.9 | Middle | |
| Operating margin | 20.2% | Middle | |
| ROE | 28.7% | High | |
| Debt/equity | 0.13 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Laboratorios Farmaceuticos Rovi. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€191.67M
Latest quarter · Q2 2026
Net income
€75M
Latest quarter · Q2 2026
Quarterly net margin
39.1%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €3.34B
- P/E
- 16.0
- EPS
- €4.08
- Volume
- 18.65K
- Daily trading
- €9.17M
- Dividend yield
- 1.52%
- Last ex-dividend on July 13, 2026
How Laboratorios Farmaceuticos Rovi is changing
All resultsRevenue grew 12.1% a year on average over the last 5 years
Operating margin fell from 31.0% to 23.3%
Less cash than profit: free cash flow equal to 58% of net income
Returns
Laboratorios Farmaceuticos Rovi returns with dividends
€1,000 invested in Laboratorios Farmaceuticos Rovi 5 years ago, on November 22, 2021, would be worth €1,128 today with dividends reinvested: +12.82% in total, +2.45% per year. On price alone it would be €1,026 (+2.60%).
| Period | Laboratorios Farmaceuticos Rovi | IBEX 35 | €1,000 becomes |
|---|---|---|---|
| 1 month | +7.50% | −1.15% | €1,075 |
| 6 months | +5.25% | +4.55% | €1,053 |
| Year to date | −0.63% | +9.04% | €994 |
| 1 year | +11.48% | +18.04% | €1,115 |
| 3 years | +26.99% | +91.82% | €1,270 |
| 5 years | +12.82% | +113.95% | €1,128 |
| 10 years | +537.56% | +119.08% | €6,376 |
Over the last 6 months it has done better than 22% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. IBEX 35: price only. Calculate your investment
The chart in detail
Laboratorios Farmaceuticos Rovi: technical analysis
Laboratorios Farmaceuticos Rovi shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 31.0% below its all-time closing high (€91.50, May 24, 2024).
- Trend
- No clear trend
- RSI (14 sessions)
- 43
- Between 30 and 70
- vs 200-session average
- −3.91%
Support and resistance
Price areas where Laboratorios Farmaceuticos Rovi has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€71.15+12.76%2 touches, last on November 12, 2026
- Last price€63.10
- Support€60.90−3.49%2 touches, last on September 29, 2026
- Support€59.83−5.19%4 touches, last on October 15, 2026
- Support€57.25−9.27%7 touches, last on October 19, 2026
Volatility and risk
Over the last year it has moved little with the IBEX 35.
- Beta (1 year) vs IBEX 35
- 0.39
- Volatility (60 sessions, annualised)
- 27.3%
- Largest fall in the last year
- −37.29%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Laboratorios Farmaceuticos Rovi: seasonality
Average monthly price change over 19 years
Over the last 19 years, the strongest month for Laboratorios Farmaceuticos Rovi has been February: +3.33% on average, positive in 13 years out of 19. The weakest has been May: −2.36% on average, positive in 11 years out of 19. November, the current month, has been positive in 10 years out of 18 (+1.60% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.51% | +2.88% | 12 of 19 |
| February | +3.33% | +3.66% | 13 of 19 |
| March | +0.68% | −0.74% | 9 of 19 |
| April | +2.24% | +0.10% | 10 of 19 |
| May | −2.36% | +0.41% | 11 of 19 |
| June | +1.78% | +1.61% | 11 of 19 |
| July | +0.34% | +1.21% | 12 of 19 |
| August | +1.75% | +1.93% | 12 of 19 |
| September | −1.06% | −1.70% | 7 of 19 |
| October | +1.45% | +0.91% | 12 of 19 |
| November | +1.60% | +2.03% | 10 of 18 |
| December | +1.31% | 0.00% | 8 of 18 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Laboratorios Farmaceuticos Rovi and its competitors
Rovi's prescription medicines, including Ameride, Exxiv, Neparvis and Mysimba, form the core of its activity, and the group also sells hospital products such as contrast agents and catheter care under the Fibrilin name. Its portfolio spans cardiology, women's health, anaesthesia and pain, the central nervous system, urology, endocrinology and respiratory care. Beyond its own brands, the company runs contract manufacturing for injectable forms, covering sterile filling, labelling, serialisation and packaging, and it also makes low-molecular-weight heparin.
- Headquarters
- Pozuelo de Alarcón, Spain
- Employees
- 1,950
- Founded
- 1946
- Chief executive
- Juan Lopez-Belmonte Encina
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Laboratorios Farmaceuticos RoviROVI | $3.68B | 20.2% | 16.0 | +5.25% |
| Siegfried HoldingSFZN | $3.4B | 16.7% | 16.7 | −19.46% |
| AlmirallALM | $2.45B | 9.6% | 30.2 | −9.84% |
| FagronFAGR | $1.97B | 14.3% | 19.5 | −0.20% |
| Faes FarmaFAE | $1.65B | 13.0% | 17.9 | +4.66% |
| H. LundbeckHLUN.A | $8.56B | 24.4% | 14.4 | +63.06% |
Same industry or related industries, similar size. Compare Laboratorios Farmaceuticos Rovi with its competitors · Full profile
More on Laboratorios Farmaceuticos Rovi
- Laboratorios Farmaceuticos Rovi revenue and financials
- Laboratorios Farmaceuticos Rovi dividend and valuation
- Laboratorios Farmaceuticos Rovi stock return
- Laboratorios Farmaceuticos Rovi employees, headquarters and business
